Masimo (NASDAQ:MASI) Issues Q3 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.81-0.86 for the period, compared to the consensus estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million. Masimo also updated its Q3 2024 guidance to 0.810-0.860 EPS.

Masimo Stock Up 0.1 %

MASI opened at $133.20 on Friday. Masimo has a fifty-two week low of $75.22 and a fifty-two week high of $153.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. The company’s 50-day moving average is $116.67 and its 200 day moving average is $124.97. The firm has a market capitalization of $7.08 billion, a P/E ratio of 90.61 and a beta of 0.98.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The firm had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 EPS. Research analysts expect that Masimo will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

MASI has been the subject of several research reports. Piper Sandler increased their price objective on Masimo from $160.00 to $165.00 and gave the company an overweight rating in a report on Wednesday, August 7th. Needham & Company LLC reissued a hold rating on shares of Masimo in a report on Friday, September 20th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Masimo has an average rating of Moderate Buy and a consensus price target of $144.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.